Cell Cycle, volume 17, issue 8, pages 974-984

LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis

Ma Pei ¹

Wang Haitao ²

SUN JIANGYANG ³

Liu Hongzhou ¹

Zheng Chao ¹

Zhou Xin ⁴

Lu Zhongxin ¹

Hide authors affiliations Show authors affiliations: 4 affiliations

Department of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China |

Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China |

Department of Hepatobiliary and Pancreas, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China |

⁴

Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China |

Publication type: Journal Article

Publication date: 2018-04-18

Taylor & Francis

Journal: Cell Cycle

Quartile SCImago

Quartile WOS

Impact factor: 4.3

ISSN: 15384101, 15514005

DOI: 10.1080/15384101.2018.1464834

Copy DOI

PubMed ID: 29895195

Molecular Biology

Cell Biology

Developmental Biology

Abstract

Long intergenic non-coding RNA 00152 (LINC00152) is aberrantly expressed in various human malignancies and plays an important role in the pathogenesis. Here, we found that LINC00152 is upregulated in hepatocellular carcinoma (HCC) tissues as compared to adjacent non-neoplastic tissues; gain-and-loss-of-function analyses in vitro showed that LINC00152 facilitates HCC cell cycle progression through regulating the expression of CCND1. LINC00152 knockdown inhibits tumorigenesis in vivo. MS2-RIP analysis indicated that LINC00152 binds directly to miR-193a/b-3p, as confirmed by luciferase reporter assays. Furthermore, ectopic expression of LINC00152 partially halted the decrease in CCND1 expression and cell proliferation capacity induced by miR-193a/b-3p overexpression. Thus, LINC00152 acts as a competing endogenous RNA (ceRNA) by sponging miR-193a/b-3p to modulate its target gene, CCND1. Our findings establish a ceRNA mechanism regulating cell proliferation in HCC via the LINC00152/miR-193a/b-3p/CCND1 signalling axis, and identify LINC00152 as a potential therapeutic target for HCC.

By date By citations

Citations by journals

	1 2 3 4 5
Frontiers in Oncology	Frontiers in Oncology, 5, 12.2% Frontiers in Oncology 5 publications, 12.2%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 2, 4.88% International Journal of Molecular Sciences 2 publications, 4.88%
Biomedicine and Pharmacotherapy	Biomedicine and Pharmacotherapy, 2, 4.88% Biomedicine and Pharmacotherapy 2 publications, 4.88%
Cell Cycle	Cell Cycle, 2, 4.88% Cell Cycle 2 publications, 4.88%
Journal of Zhejiang University: Science B	Journal of Zhejiang University: Science B, 2, 4.88% Journal of Zhejiang University: Science B 2 publications, 4.88%
BioMed Research International	BioMed Research International, 2, 4.88% BioMed Research International 2 publications, 4.88%
Doklady Biochemistry and Biophysics	Doklady Biochemistry and Biophysics, 1, 2.44% Doklady Biochemistry and Biophysics 1 publication, 2.44%
Oncotarget	Oncotarget, 1, 2.44% Oncotarget 1 publication, 2.44%
DNA and Cell Biology	DNA and Cell Biology, 1, 2.44% DNA and Cell Biology 1 publication, 2.44%
Oncology Letters	Oncology Letters, 1, 2.44% Oncology Letters 1 publication, 2.44%
International Journal of Oncology	International Journal of Oncology, 1, 2.44% International Journal of Oncology 1 publication, 2.44%
Cancers	Cancers, 1, 2.44% Cancers 1 publication, 2.44%
Genes	Genes, 1, 2.44% Genes 1 publication, 2.44%
Cells	Cells, 1, 2.44% Cells 1 publication, 2.44%
Frontiers in Molecular Biosciences	Frontiers in Molecular Biosciences, 1, 2.44% Frontiers in Molecular Biosciences 1 publication, 2.44%
Cellular and Molecular Life Sciences	Cellular and Molecular Life Sciences, 1, 2.44% Cellular and Molecular Life Sciences 1 publication, 2.44%
Hereditas	Hereditas, 1, 2.44% Hereditas 1 publication, 2.44%
Cell Death and Disease	Cell Death and Disease, 1, 2.44% Cell Death and Disease 1 publication, 2.44%
Pathology Research and Practice	Pathology Research and Practice, 1, 2.44% Pathology Research and Practice 1 publication, 2.44%
Gene	Gene, 1, 2.44% Gene 1 publication, 2.44%
International Immunopharmacology	International Immunopharmacology, 1, 2.44% International Immunopharmacology 1 publication, 2.44%
Genes and Diseases	Genes and Diseases, 1, 2.44% Genes and Diseases 1 publication, 2.44%
Journal of Cellular Biochemistry	Journal of Cellular Biochemistry, 1, 2.44% Journal of Cellular Biochemistry 1 publication, 2.44%
Journal of Clinical Laboratory Analysis	Journal of Clinical Laboratory Analysis, 1, 2.44% Journal of Clinical Laboratory Analysis 1 publication, 2.44%
Open Medicine (Poland)	Open Medicine (Poland), 1, 2.44% Open Medicine (Poland) 1 publication, 2.44%
Disease Markers	Disease Markers, 1, 2.44% Disease Markers 1 publication, 2.44%
Genomics and Informatics	Genomics and Informatics, 1, 2.44% Genomics and Informatics 1 publication, 2.44%
Cancer Management and Research	Cancer Management and Research, 1, 2.44% Cancer Management and Research 1 publication, 2.44%
Journal of Cellular Physiology	Journal of Cellular Physiology, 1, 2.44% Journal of Cellular Physiology 1 publication, 2.44%
Human Antibodies	Human Antibodies, 1, 2.44% Human Antibodies 1 publication, 2.44%
	1 2 3 4 5

Citations by publishers

	1 2 3 4 5 6
Frontiers Media S.A.	Frontiers Media S.A., 6, 14.63% Frontiers Media S.A. 6 publications, 14.63%
Elsevier	Elsevier, 6, 14.63% Elsevier 6 publications, 14.63%
Multidisciplinary Digital Publishing Institute (MDPI)	Multidisciplinary Digital Publishing Institute (MDPI), 5, 12.2% Multidisciplinary Digital Publishing Institute (MDPI) 5 publications, 12.2%
Springer Nature	Springer Nature, 4, 9.76% Springer Nature 4 publications, 9.76%
Wiley	Wiley, 4, 9.76% Wiley 4 publications, 9.76%
Hindawi Limited	Hindawi Limited, 3, 7.32% Hindawi Limited 3 publications, 7.32%
Spandidos Publications	Spandidos Publications, 2, 4.88% Spandidos Publications 2 publications, 4.88%
Taylor & Francis	Taylor & Francis, 2, 4.88% Taylor & Francis 2 publications, 4.88%
Zhejiang University Press	Zhejiang University Press, 2, 4.88% Zhejiang University Press 2 publications, 4.88%
Pleiades Publishing	Pleiades Publishing, 1, 2.44% Pleiades Publishing 1 publication, 2.44%
Impact Journals	Impact Journals, 1, 2.44% Impact Journals 1 publication, 2.44%
Mary Ann Liebert	Mary Ann Liebert, 1, 2.44% Mary Ann Liebert 1 publication, 2.44%
Walter de Gruyter	Walter de Gruyter, 1, 2.44% Walter de Gruyter 1 publication, 2.44%
Korea Genome Organization	Korea Genome Organization, 1, 2.44% Korea Genome Organization 1 publication, 2.44%
Dove Medical Press	Dove Medical Press, 1, 2.44% Dove Medical Press 1 publication, 2.44%
IOS Press	IOS Press, 1, 2.44% IOS Press 1 publication, 2.44%
	1 2 3 4 5 6

We do not take into account publications that without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0],"codes":[0,0,0,0,0,0],"imageUrls":["","","","","",""],"datasets":[{"label":"Citations number","data":[8,8,12,5,7,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["19.51","19.51","29.27","12.2","17.07","2.44"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Frontiers in Oncology","International Journal of Molecular Sciences","Biomedicine and Pharmacotherapy","Cell Cycle","Journal of Zhejiang University: Science B","BioMed Research International","Doklady Biochemistry and Biophysics","Oncotarget","DNA and Cell Biology","Oncology Letters","International Journal of Oncology","Cancers","Genes","Cells","Frontiers in Molecular Biosciences","Cellular and Molecular Life Sciences","Hereditas","Cell Death and Disease","Pathology Research and Practice","Gene","International Immunopharmacology","Genes and Diseases","Journal of Cellular Biochemistry","Journal of Clinical Laboratory Analysis","Open Medicine (Poland)","Disease Markers","Genomics and Informatics","Cancer Management and Research","Journal of Cellular Physiology","Human Antibodies"],"ids":[10990,14627,23951,16553,4222,8750,3773,8484,755,9773,18049,22471,8879,25293,3133,5151,19583,25236,2120,2111,11569,17383,20085,8452,4403,1909,15077,17233,4815,2529],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp","\/storage\/images\/resized\/HY0CXgRt044tzIAB16PDvDzdHeKHGtSvlMH0yWf6_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/8zKfOwdd5XirYzTQfqwp7U8IEQc8ckIOjyYQSBkk_medium.webp","\/storage\/images\/resized\/8zKfOwdd5XirYzTQfqwp7U8IEQc8ckIOjyYQSBkk_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/3SpVxcYL33bOvPq4sHxJLH2NeKNeDloahSUpNiO4_medium.webp","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/KqWdDIHwzps3KNMz2kSZBC4SgMnkL3bwEKJqtZ2u_medium.webp"],"datasets":[{"label":"","data":[5,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[12.2,4.88,4.88,4.88,4.88,4.88,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44,2.44],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Frontiers Media S.A.","Elsevier","Multidisciplinary Digital Publishing Institute (MDPI)","Springer Nature","Wiley","Hindawi Limited","Spandidos Publications","Taylor & Francis","Zhejiang University Press","Pleiades Publishing","Impact Journals","Mary Ann Liebert","Walter de Gruyter","Korea Genome Organization","Dove Medical Press","IOS Press"],"ids":[208,17,202,8,11,6921,1097,18,1497,101,342,230,4,4494,417,29],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","\/storage\/images\/resized\/8zKfOwdd5XirYzTQfqwp7U8IEQc8ckIOjyYQSBkk_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","","\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp","\/storage\/images\/resized\/HY0CXgRt044tzIAB16PDvDzdHeKHGtSvlMH0yWf6_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/3SpVxcYL33bOvPq4sHxJLH2NeKNeDloahSUpNiO4_medium.webp","","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/KqWdDIHwzps3KNMz2kSZBC4SgMnkL3bwEKJqtZ2u_medium.webp"],"datasets":[{"label":"","data":[6,6,5,4,4,3,2,2,2,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[14.63,14.63,12.2,9.76,9.76,7.32,4.88,4.88,4.88,2.44,2.44,2.44,2.44,2.44,2.44,2.44],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}

Metrics

Cite this

GOST |

Cite this

GOST Copy

Ma P. et al. LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis // Cell Cycle. 2018. Vol. 17. No. 8. pp. 974-984.

GOST all authors (up to 50) Copy

Ma P., Wang H., Wang H., SUN J., Liu H., Zheng C., Zheng C., Zhou X., Lu Z. LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis // Cell Cycle. 2018. Vol. 17. No. 8. pp. 974-984.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1080/15384101.2018.1464834

UR - https://doi.org/10.1080%2F15384101.2018.1464834

TI - LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis

T2 - Cell Cycle

AU - Ma, Pei

AU - Wang, Haitao

AU - SUN, JIANGYANG

AU - Liu, Hongzhou

AU - Zheng, Chao

AU - Lu, Zhongxin

AU - Wang, Haitao

AU - Zheng, Chao

AU - Zhou, Xin

PY - 2018

DA - 2018/04/18 00:00:00

PB - Taylor & Francis

SP - 974-984

IS - 8

VL - 17

PMID - 29895195

SN - 1538-4101

SN - 1551-4005

ER -

BibTex |

Cite this

BibTex Copy

@article{2018_Ma,

author = {Pei Ma and Haitao Wang and JIANGYANG SUN and Hongzhou Liu and Chao Zheng and Zhongxin Lu and Haitao Wang and Chao Zheng and Xin Zhou},

title = {LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis},

journal = {Cell Cycle},

year = {2018},

volume = {17},

publisher = {Taylor & Francis},

month = {apr},

url = {https://doi.org/10.1080%2F15384101.2018.1464834},

number = {8},

pages = {974--984},

doi = {10.1080/15384101.2018.1464834}

}

MLA

Cite this

MLA Copy

Ma, Pei, et al. “LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis.” Cell Cycle, vol. 17, no. 8, Apr. 2018, pp. 974-984. https://doi.org/10.1080%2F15384101.2018.1464834.

Found error?

Publisher

Taylor & Francis

Journal

Cell Cycle

Quartile SCImago

Quartile WOS

Impact factor

4.3

ISSN

15384101 (Print)
15514005 (Electronic)